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Abstract
In mammalian cells, heme can be degraded by heme-oxygenases (HO). Heme-oxygenase 1 (HO-1) is known to be the heme
inducible isoform, whereas heme-oxygenase 2 (HO-2) is the constitutive enzyme. Here we investigated the presence of HO
during erythroid differentiation in human bone marrow erythroid precursors and K562 cells. HO-1 mRNA and protein
expression levels were below limits of detection in K562 cells. Moreover, heme was unable to induce HO-1, at the protein
and mRNA profiles. Surprisingly, HO-2 expression was inhibited upon incubation with heme. To evaluate the physiological
relevance of these findings, we analyzed HO expression during normal erythropoiesis in human bone marrow. Erythroid
precursors were characterized by lack of significant expression of HO-1 and by progressive reduction of HO-2 during
differentiation. FLVCR expression, a recently described heme exporter found in erythroid precursors, was also analyzed.
Interestingly, the disruption in the HO detoxification system was accompanied by a transient induction of FLVCR. It will be
interesting to verify if the inhibition of HO expression, that we found, is preventing a futile cycle of concomitant heme
synthesis and catabolism. We believe that a significant feature of erythropoiesis could be the replacement of heme
breakdown by heme exportation, as a mechanism to prevent heme toxicity.
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Introduction
Hematopoiesis is a tightly coordinated process involving a
network of multiple signals, such as cytokines, hormones, and
cellular cooperation, to promote hematopoietic stem cell (HSC)
self-renewal and multilineage differentiation into distinct blood cell
types. In adult mammals, bone marrow (BM) is the primary site for
production of red blood cells (RBCs). The production of RBC
requires an exceptionally high rate of heme biosynthesis to allow
massive accumulation of hemoglobin in erythroblasts [1,2]. It is
well established in literature that heme acts as a regulator of its
own synthesis, as well as a positive modulator of globin
polypeptide chain synthesis in erythroblasts [3,4]. Recently, heme
has been ascribed a broader role as a critical modulator of cell
signaling pathways, controlling gene expression, protein transla-
tion and post-translational protein modifications such as phos-
phorylation and ubiquitinylation [5,6]. Based on the previous
findings, heme-oxygenase has emerged, capable of controlling
heme levels, preventing neuronal damage, regulating inflamma-
tion, and participating in vascular function [7,8,9].
Although heme is a signaling molecule and has obvious
physiological relevance as the prosthetic group of hemeproteins,
it is also a potential hazardous molecule capable of inducing
reactive oxygen species leading to cell damage [10,11]. Therefore,
cellular heme levels are tightly regulated by a fine balance between
its biosynthesis and catabolism [12]. Heme oxygenases are
ubiquitous enzymes that degrade heme to ferrous iron, carbon
monoxide (CO) and biliverdin. HO-2 isoform is constitutively
expressed, whereas HO-1 is induced by multiple stress stimuli
[13,14,15]. The primary mechanism to prevent free heme
accumulation inside cells involves heme inducing HO-1 expres-
sion. According to the literature, it is generally assumed that
intracellular free heme is rapidly degraded by HO, which is most
frequently regarded as the major cytoprotective enzyme [16,17].
In most cell types, induction of HO is accompanied by suppression
of the ubiquitous isoform of 5-aminolevulinate synthase (ALAS-1),
the rate-limiting reaction in the heme synthesis pathway [5]. The
ALAS-2 isoform is exclusive to the erythroid lineage, and its
expression is induced even in the presence of high heme
concentrations during erythropoiesis [18,19,20]. Although in-
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production, the regulation of the heme degradation pathway
during erythroid differentiation has been largely overlooked.
In the study presented, we assessed the expression of HO
isoforms during human erythroid differentiation. Initially, the in
vitro model used a human erythroleukemia cell line (K562)
undergoing heme-induced erythroid differentiation. The physio-
logical pattern of HO expression during erythropoiesis was
investigated in human bone marrow samples. The evaluation of
heme metabolism enzymes in the different maturation stages of
erythroid precursors was performed using multiparameter flow
cytometry immunophenotyping. In addition, the presence of
alternative routes to heme detoxification, such as the recently
discovered heme exporter FLVCR (feline leukemia virus,
subgroup C, receptor), was investigated.
Materials and Methods
Ethics Statement
It was used in this work samples obtained from human bone
marrow. All subjects gave their informed consent prior to entering
the study, and the study was approved by the local Ethics
Committee of the University Hospital of Salamanca (Salamanca,
Spain).
Cell lines
The K562, THP-1 and RAW264.7 cell lines were obtained
from the American Type Culture Collection (ATCC- Rockville,
MD, USA). Murine RAW 264.7 cells were maintained in DMEM
medium with 10% fetal bovine serum (FBS) (Invitrogen, Carlsbad,
CA, USA) whereas both K562 and THP-1 human cell lines were
cultured in RPMI 1640 (Invitrogen, Carlsbad, CA, USA),
supplemented with 10% FBS. Cultures were maintained at 37uC
in a 5% CO2 humidified incubator. In order to induce erythroid
differentiation of K562 cells or analyze heme metabolism in two
additional cell lines, cells were incubated with heme (0.2, 2.0 or
20 mM) for 24, 48, and 72 h. A 20 mM heme stock solution in
dimethylsulfoxide (Me2SO) was diluted to 2 mM in 0.25 M
NaOH. This solution was further diluted to 0.4 mM in culture
medium immediately prior to use and was added to cell cultures at
a desired final concentration. This serial dilution was used to
preserve heme solubility in the final incubation media (pH 7.4).
Patients and samples
A total of 10 ethylenediaminetetraacetic acid (EDTA)-antico-
agulated BM samples were obtained from the same number of
volunteers at the University Hospital of Salamanca (Salamanca,
Spain) and analyzed in the present study. Within this group, six
corresponded to BM aspirate samples obtained from lymphoma
staging in patients which did not show evidence of any bone
marrow expanded clonal population. One sample was from a
woman that had two previous episodes of anaphylaxis and the
absence of any clonal mast cell disease was found from BM
analysis. In the other three BM aspirate samples, the diagnosis of
myelodisplasic syndrome was excluded using both WHO criteria
and the multiparametric flow citometry analysis. We performed
the morphological and immunophenotypical evaluation of ery-
throid maturation in these BM samples, and all of them
systematically showed patterns consistent with normal differenti-
ation. All subjects gave their informed consent prior to entering
the study, and the study was approved by the local Ethics
Committee of the University Hospital of Salamanca (Salamanca,
Spain).
Western Blot studies
Cell lysates were prepared using SDS-sample buffer containing
b-mercaptoethanol; they were submitted to electrophoresis in 7.5–
20% acrylamide gradient SDS-PAGE gels [21]. All the westerns
were performed with the usage of the Prestained Rainbow
Molecular Weight Marker (GE Healthcare). The samples were
transferred onto nitrocellulose membranes (Bio-Rad, Hercules,
CA, USA) and non-specific binding sites were blocked with 5%
non-fat milk in Tris buffered saline-Tween 20 (TBST; 50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 0.05% Tween 20). Membranes
were probed with anti-HO-1, anti-HO-2 (Assay Designs, Ann
Arbor, MI, USA) and anti-b-actin (BD Biosciences, Franklin
Lakes, NJ, USA) monoclonal antibodies (mAb) in TBST with 1%
non-fat dry milk. The membranes were incubated with a
horseradish peroxidase (HRP)-conjugated secondary antibody in
TBST, followed by detection of antigen-antibody complexes using
a Supersignal Chemiluminescence kit (Pierce, Rockford, IL, USA).
Densitometric analysis of images from developed film was
performed using the Image 2D software (GE Healthcare).
Real-time PCR analysis
Whole RNA samples derived from the three cell lines were
extractedfrom10
6 cellsusingTRIzolreagent (Invitrogen,Carlsbad,
CA, USA). RNA extraction from human BM cells was performed
using the Nucleospin RNA XS Kit (Macherey-Nagel, Du ¨ren,
Germany), as recommended by the manufacturer. First strand
cDNA was synthesized using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA, USA),
following the specification provided in the kit protocol. PCR
amplification of the selected genes was carried out using specific
primers, as described in Table S1. Real-Time PCR was performed
in an ABI 7500 Real-Time PCR System (Applied Biosystems) using
the SYBR Green I double-stranded DNA-specific fluorophore
(Power SYBRH Green PCR Master Mix; Applied Biosystems).
cDNAs were amplified using a 40-cycle reaction of denaturation
(15 s, 95uC) and annealing/extension (60 s, 60uC). Formation of a
single product was determined by melt curve analysis. Quantifica-
tion of mRNA was performed by comparative Ct and GAPDH
mRNA was used as endogenous reference. The fold increase above
control levels was obtained through the calculation of 2 2DDCt,
where DDCt=DCt treatment2DCt control [22].
Multiparameter Flow Cytometry immunophenotyping
studies
In order to evaluate HO-1 expression, whole BM samples were
fixed with solution A from the Fix & Perm
TM kit (Invitrogen) for
15 min at room temperature (RT); they were subsequently washed
with PBS containing 0.2% bovine serum albumin (BSA) and
centrifuged for 5 min at 540 g. The BM cells were incubated
(15 min at RT) with solution B from the Fix & Perm
TM and FITC-
conjugated anti-human HO-1 mAb (Assay Designs, Ann Arbor,
MI, USA) and washed with PBS containing 0.2% BSA (5 min at
540 g). Assessment of FLVCR expression was performed on
erythrocyte-lysed BM samples in FACS-lysing solution [Becton
Dickinson Biosciences (BD), San Jose ´, CA] diluted 1:10 (v/v) in
distilled water. Briefly, erytrocyte-lysed samples were sequentially
washed in PBS containing 0.2% BSA, incubated with an anti-
FLVCR mAb (ABNOVA) for 15 min (RT) and washed in PBS
containing 0.2% BSA. Next, the cells were incubated with a FITC-
conjugate anti-mouse IgG reagent (Cytognos SL, Salamanca,
Spain) for 15 min in the dark (RT) and were washed in PBS
containing 0.2% BSA. Finally, samples stained with HO-1 and
FLVCR were both incubated (15 min at RT in the darkness) with
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These were used to define the distinct stages of maturation of BM
erythroid precursors (CD45-Pacific Blue, CD71-APC, CD105-PE
and CD34-PerCP-Cy5.5) and to specifically identify BM erythroid
precursors and monocytes (CD45-Pacific Blue, CD71-APC, CD36-
PE). A final wash step was performed with PBS (5 min at 540 g).
Stained BM samples were analyzed in a FACS Canto II flow
cytometer equipped with FACSDiVa software (BD); data analysis
was performed with the Infinicyt software (Cytognos). BM erythroid
precursors were identified as FSC
lo/SSC
lo/CD34
2/CD45
2/
CD71
++/CD61
2 cells, and monocytes as FSC
hi/SSC
lo/CD34
2/
CD36
+/CD45
hi/CD61
2 cells (figure S1). Purification of different
compartments of stained BM cells was performed with a FACSAria
flow cytometer (BD), as illustrated in Figure S1. FACS-sorted cells
were collected in PBS and re-analyzed for purity, which was
systematically .98%. Sorted cells were stored at 270uC in solution
RA1 of the Nucleospin RNA XS Kit (Macherey-Nagel).
Statistical Analyses
Data were reported as mean values 6 SEM and were analyzed
statistically by means of analysis of variance followed by a Student
t-test using the SPSS software package (SPSS, Chicago, IL, USA)
or by the one-way analysis of variance and a posteriori Tukey’s
test, using GraphPad Prism version 5.00 software (GraphPad
Software, San Diego, CA, USA).
Results
Induction of synthesis of hemoglobin by heme in K562
cells
The human K562 erythroleukemia cell line mimics a common
megakaryocyte-erythroid BM progenitor [23]. K562 cells have
been used as a model for erythropoiesis since exposure of these
cells to heme and other substances, such as sodium butyrate, have
been reported to increase expression of globin mRNA [18,24,25].
As heme is likely a physiological stimulus, heme-induced erythroid
differentiation under cell culture conditions was studied. Incuba-
tion of K562 cells with heme (20 mM) for 48 h strongly induced
hemoglobin synthesis, as evidenced by the intense red color of the
cell pellet (Figure 1A). The color is a consequence of the light
absorption spectrum characteristic of hemoglobin with the heme
bound at heme-pocket (Soret band at 415 nm and a and b bands
at 542 nm and 577 nm) (Figure 1B) [26].
Absence of heme-oxygenase 1 in K562 cells
Heme is known to increase expression of HO-1, the inducible
isoform of HO. Therefore, K562 was used as a model to analyze
the heme degradation pathway under a condition of intense
hemoglobin synthesis. When incubated only with culture medium,
no detectable expression of HO-1 in K562 cells was found as
observed by western blot and confirmed by real-time PCR
(Figure 2 A, B). Moreover, exposure of K562 cells to high
concentrations of heme (20 mM) did not elicit HO-1 expression
after 4 h or 24 h (Figure 2A). The lack of measurable expression in
K562 cells was also observed at different time points after addition
of heme to the culture medium (48 and 72 h; data not shown).
RAW264.7 cells (mouse macrophage cells) and THP-1 human
monocytic cells were used as positive controls, as incubation in the
presence of heme promptly (4 h and 24 h) resulted in strong
expression of HO-1 (Figures 2A and B).
Heme downregulation of heme-oxygenase-2 expression
Heme-oxygenase 2 is usually referred as the constitutively
expressed isoform of HO and is usually not explored in most
studies addressing regulation of heme degradation. As HO-1 was
not induced in K562 cells, a possible compensatory stimulation of
HO-2 was investigated. Unexpectedly, instead of increased HO-2
expression, exposure of K562 cells to heme inhibited HO-2
protein expression in a dose-dependent mode (Figure 3A and 3B).
As expected in RAW 264.7 cells, the HO-2 levels were not
influenced by heme (Figure 3A). The results obtained by Western
blot were further supported by real-time PCR, which indicated
that HO-2 mRNA was inhibited under heme-induced erythroid
differentiation (Figure 3C). As expected, the human control THP-
1 cells showed a lack of modulation of HO-2 by heme.
Lack of heme oxygenase-1 and inhibition of HO-2
expression in human bone marrow erythroid precursors
The unusual behavior of the heme degradation pathway could
be attributed to an anomaly unique to K562 malignant cell line.
Figure 1. Heme induces erythroid differentiation by increasing
hemoglobin synthesis in K562 cells. K562 cells were cultured for
48 h in the absence or presence of heme (20 mM) (A) cell pellet of
erythroid differentiated culture with an intense red color when
compared with the control. (B) Spectrophotometric analysis of the
control (
…..) and heme stimulated (
___) cell lysates obtained from the
pellets shown in panel A. Visible light absorption spectrum character-
istic of hemoglobin. The arrows indicate the characteristic wavelenght
peaks of hemoglobin absorption the Soret band at 415 nm and a and b
bands at 542 nm and 577 nm.
doi:10.1371/journal.pone.0021358.g001
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of HO-2 and the lack of HO-1 expression would also be found
during normal erythropoiesis in human BM. Erythroid precursors
from BM samples showed undetectable levels of HO-1 expression,
similar to what was found in K562 cells (Figure 4A and Figure 4B).
These results suggested that in human BM, normal erythropoiesis
occured without heme degradation by HO-1. Noteworthy, HO-1
expression was clearly limited to the monocyte population while
the other BM cell compartments showed an absence of labeling for
HO-1 (Figure 4A and Figure 4B).
In order to gain insight into the regulation of heme catabolism
during erythropoiesis, human BM erythroid precursors were
further classified into three maturation-associated subpopulations
according to the pattern of expression of both CD105 and
CD71(Figure S1) [27,28]. The more immature erythroid precur-
sors showed a CD105
2/CD71
lo phenotype, intermediate cells
were CD105
+/CD71
hi, and the major compartment of more
Figure 2. Modulation of heme-oxygenase 1 by heme during
erythroid differentiation of K562 cells. (A) Western Blot analysis of
K562 and RAW 264.7 cell lysates for HO-1 expression. K562 and RAW
264.7 cultures were incubated with or without heme (20 mM) for 24 h.
RAW 264.7 was a positive control of heme oxygenase-1 induction after
4 h or 24 h of heme treatment. Actin detection serves as a loading
control. (B) Relative expression of HO-1 mRNA in K562 and THP-1 cells
under control conditions and after stimulation with heme (20 mM) for
24 h. The graph displays the average values of three independent
experiments with internal biological triplicates of a real-time PCR
quantification assays. Results were systematically normalized by GAPDH
expression. The THP-1 control was used as a reference to calculate the
relative expression, and it was set at one. The analysis of variance
(ANOVA) indicated significant differences (*p,0.001) for THP-1 but not
K562 cells.
doi:10.1371/journal.pone.0021358.g002
Figure 3. Heme inhibits the constitutive isoform of heme
oxygenase (HO) HO-2 in K562 cells. (A) Western Blot analysis of
K562 and RAW 264.7 cell lysates to determine HO-2 expression. K562
and RAW 264.7 cell cultures were incubated in absence or presence of
heme (20 mM) for 48 h. Actin detection was used as loading control. (B)
Western Blot analysis of K562 cells cultured with increasing concentra-
tions (0, 0.2, 2.0 or 20 mM) of heme. The graph represents the results of
three independent experiments normalized by actin expression. (C)
Relative expression of HO-2 mRNA in K562 and THP-1 cells incubated in
the presence or absence of heme (20 mM) for a period of 24 h. The
graph shows the average results of three independent experiments
with internal biological triplicates of a real-time PCR assay, normalized
by GAPDH expression. The THP-1 control was used as a reference to
calculate relative expression, and it was set at one. * p,0.05; ** p,0.01.
doi:10.1371/journal.pone.0021358.g003
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2/
CD71
hi phenotypic profile (Figure S1). The maturation of these
three BM NRBC compartments was validated by real-time PCR,
which showed a progressive increase in mRNA expression of both
glycophorin A and ALAS-2, that are respectively, a major
component of the red cell membrane and the erythroid-specific
isoform of ALAS (Figure 5A and C). The progression of erythroid
maturation in the subpopulations that were identified using this
approach received further support from the decrease in the
expression of ALAS-1, which was known to occur during
erythropoiesis (Figure 5 B) [29,30,31]. BM monocytes were used
as internal positive control for HO-1 (Figure 5 D).
Similar to what was described above (Figure 4), real-time PCR
revealed that HO-1 mRNA levels were actually below detection
limits in all BM compartments of NRBC precursors (Figure 5D).
Remarkably, HO-2 mRNA expression was progressively down-
regulated during the course of erythroid differentiation (Figure 5E).
FLVCR expression during normal human erythropoiesis
Erythropoiesis was characterized by a dramatic increase in the
intracellular heme/hemoglobin contents. Since erythroid precur-
sor cells lack HO-1 and there is a progressive decrease in HO-2
expression during maturation, we hypothesized that these cells
might use alternative mechanisms to protect themselves against
Figure 4. Expression of HO-1 by normal human BM erythroid precursors and monocytes. (A) Flow cytometry analysis of HO-1 antigen
expression in erythroid precursors (dark grey dots) gated as FSC
lo/SSC
lo/CD34
2/CD45
2/CD71
++/CD61
2 cells and the monocytic population (black
dots) were identified as FSC
hi/SSC
lo/CD34
2/CD36
+/CD45
hi/CD61
2. Other BM cells are displayed as light gray events/dots. Expression of HO-1 (A right
panel) was compared to the isotypic control (A left panel). (B) Histogram obtained from the date in panel A comparing the fluorescence intensity of
isotypic control (dotted line) and anti HO antibody (continuous line) in erythroblasts or monocytes. (C) Box plot representing mean fluorescence
intensity (MFI, arbitrary units – A.U.-form 0 to 262144 channels) values obtained for HO-1 protein expression divided by the MFI of the isotypic control
for normal human BM erythroid precursors and monocytes in five bone marrow samples described under Methods (*p=0.01).
doi:10.1371/journal.pone.0021358.g004
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FLVCR heme exporter plays an important role during erythroid
differentiation. Analysis of FLVCR expression during normal BM
maturation of erythroid precursors showed that maximal expres-
sion occurs at the intermediate (CD105
+/CD71
hi) stage of
maturation (Figure 5F). In Figure 6 it is shown the erythroid
differentiation protein expression pattern, considering our data for
the human bone marrow on figure 4, figure 5 and figure S1.
Discussion
Commitment of hematopoietic stem cells to the erythroid
lineage was accompanied by expression of proteins such as
glycophorin A, ALAS-2 and by intense production of hemoglo-
bin and heme. Reorganization of the heme and iron metabolism
in a unique manner is a key step in the making of the red cell
[33]. The ALAS-1 isoform is inhibited by a high intracellular
concentration of heme, while the ALAS-2 is not repressed by
heme; in turn, ALAS-2 is responsible for intense heme synthesis
during erythropoiesis and the increased availability of heme is
required for hemoglobin synthesis [18,19,34]. Intracellular heme
is able to stimulate globin mRNA translation. There are known
redundant pathways to modulate globin and heme synthesis in
those cells [20,35,36]. Comparatively, little is known about the
role of HO enzymes during the formation of red cells. Elevated
concentrations of heme are not found in most non erythroid
cells. HOs promptly degrades free heme from de novo synthesis
that is not incorporated into hemeproteins, or from degradation
Figure 5. Profile of heme metabolic enzymes, FLVCR and glycophorin A expression during erythroid maturation in adult human
BM. (A–E) Expression levels of mRNA for glycophorin A, ALAS-1, ALAS-2, HO-1 and HO-2 at different stages of maturation of erythroid precursors
(stage 1: CD45
2, CD105
+, CD71
+ cells; stage 2: CD45
2, CD105
++, CD71
+ cells, and stage 3: CD45
2, CD105
2, CD71
++ cells) and monocytes (in D)
(CD45
+, CD36
+, CD34
2 cells) as detected by Real Time PCR. The histograms are representative of five independent experiments using BM samples
from five patients described under Methods, with internal triplicates, normalized by GAPDH expression on FACS-purified populations (see Figure S1).
(F) Flow cytometric expression of FLVCR is shown for the same cell subpopulations. The box extends from the 25
th to the 75
th percentile and the line
at the middle is the median. The whiskers extend down to the lowest value and up to the highest. Analysis of variance (ANOVA) and Tukey’s Test was
made to indicate statistical differences (*p,0.01).
doi:10.1371/journal.pone.0021358.g005
HO Expression in Human Erythropoiesis
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here that the need to build-up high levels of intracellular heme
during erythropoiesis is accompanied by suppression of heme
degradation by heme-oxygenases.
HO-1 is the inducible isoform of heme-oxygenase, whose
expression is strongly stimulated by heme. This is true for the
majority of the mammalian cells studied thus far. K562 cells have
been extensively used as a model to study erythroid differentiation.
Although some reports in the literature showed a heme
degradation pathway in K562 [18,37], we were not able to detect
HO-1 expression in K562 cells, even when exposed to high
concentrations of heme. Some authors used K562 cells transfected
with constructs expressing the HO-1 gene, instead of studying
native expression of HO-1 [38]. This could be attributed to the
fact that most of those previous reports have evaluated heme-
oxygenase enzyme activity without identifying the isoform
involved [39]. Lavrovsky et al. [40] has identified HO-1 expression
in K562 based on Northern blot experiments. These discrepancies
could be attributed to the use of more sensitive and specific
methods (Q-PCR and western blot), different from those employed
in the previous reports. We concluded that the results presented
indicate that the previous reports on HO activity in K562 cells
may reflect the presence of the HO-2 isoform and not HO-1.
The results obtained with the K562 cell line were intriguing and
led us to investigate the pattern of HO-1 expression under
physiological conditions in human bone marrow. In support of
these findings, human BM erythroid precursors at different stages
of maturation also showed undetectable amounts of both the HO-
1 protein and mRNA. Macrophages are responsible for degrada-
tion of most of the heme from hemoglobin in mammalian
organisms, and are known to express HO-1 [15,41,42]. Coher-
ently, high levels of HO-1 were found both in the THP1 and
RAW cell lines, as well as in human BM monocytic precursors,
serving as a positive control for heme-induced HO-1 expression.
Because monocytes have a common precursor with the erythroid
lineage, the results suggest that loss of HO-1 expression is an early
event during erythropoiesis, which could even occur at the split
between the monocyte/neutrophil vs red cell/platelet committed
precursors.
Although HO-2 is known to be a constitutive enzyme that is
frequently ascribed a housekeeping role, reports have shown that
its expression is actively modulated in response to ischemia/
hypoxia [43] or tissue injury [44]. This led us to evaluate a possible
role of HO-2 in compensating for the loss of HO-1 in the erythroid
precursors. Our results indicated the opposite, a marked down-
regulation of expression of HO-2 during human bone marrow
erythroid differentiation. We do not know the correct mechanism
that is responsible for the reduction of HO-2 activity under
physiological conditions. However, in K562 cells, HO-2 expres-
sion was down-regulated in response to exposure to increased
levels of heme. That suggested that increased heme may be the
signaling event that, in the erythroid precursors, is responsible for
suppression of heme degradation.
A question that emerged from these results was why in the
erythroid precursor lineage heme should prevent its own
degradation, in opposition of what has been described for all
other cell types. Most literature reports pointed to an anti-oxidant
property of HO because heme is known to be a pro-oxidant
molecule. However, it has been shown that cleavage of heme by
HO can also exert a pro-oxidant effect under specific conditions;
this is particularly true when an increased iron availability exists,
since the reaction catalyzed by HO generates free iron that can
participate in the Fenton reaction [10]. During erythropoiesis, it
has been shown that ferritin synthesis is down-regulated to
increase iron availability and heme biosynthesis and allows for the
accumulation of hemoglobin [34]. The reduced HO activity
reported could prevent both iron overload and occurrence of
oxidative stress. Also, HO suppression may prevent an unneces-
sary cycle of concomitant heme synthesis and catabolism.
Reduction of total HO activity during erythropoiesis has been
previously reported. Hoffman et al [45] and Trakshel et al [46]
have shown that heme reduced HO total activity in K562 cells,
and Fujita et al [47] reported that MEL cells (Friend-virus
transformed erythroleukemia) exhibited a transient alteration of
HO activity. However, these pioneering observations did not
receive attention in the literature, probably because HO isoforms
themselves had not been discriminated and have only recently
been recognized to play a major regulatory role in cell physiology.
The hypothesis that disruption of the heme degradation
pathways could reflect an adaptation to allow for hemoglobin
accumulation during erythropoiesis led us to search for additional
mechanisms that could also contribute to prevent or counteract
heme toxicity. Recently, Quigley [48] showed that the Feline
Leukemia Virus Cell Receptor acts as a heme exporter protein
which is essential to erythropoiesis. Resting K562 cells showed low
expression of FLVCR; however, when these cells were committed
to erythroid differentiation, inhibition of this heme exporter
promotes apoptosis. Later, Keel et al. [32] demonstrated that
disruption of FLVCR expression in mice promoted defective
erythropoiesis and the animals died during gestation. Further-
Figure 6. Schematic representation of heme oxygenase (HO-1
and HO-2) and FLCVR expression during human BM erythro-
poiesis. Expression profile of FLVCR, HO-1 and HO-2 and ALAS-1, ALAS-
2 and Glycophorin A (Glyc.A) is displayed at different stages of BM
erythroid precursors that are defined according to the expression of
CD71 and CD105.
doi:10.1371/journal.pone.0021358.g006
HO Expression in Human Erythropoiesis
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were associated to low expression of FLVCR in Blackfan-
Diamond anemia, indicating that this may be relevant for the
establishment of the disease [49]. It was proposed that these effects
could be a consequence of incomplete erythropoiesis due to
inability to export the excess of heme. It was discovered that
FLVCR expression increased in human BM nucleated red blood
cell precursors (NRBC) during the course of erythropoiesis,
peaking at the intermediate stage of maturation, and decreasing
at later stages in the more mature CD105
2/CD71
hi NRBC
(figure 6). This result is consistent with the key role suggested for
FLVCR during erythropoiesis [32]. As these cells do not express
HO-1 and show progressive suppression of HO-2 expression,
FLVCR-mediated heme export might be understood as a
safeguard mechanism that would prevent accumulation of heme
in excess of the capacity of the cell to use it for hemoglobin
synthesis.
In summary, the data indicated that the mechanisms of
regulating heme degradation described to be common to eukaryotic
cells are subverted during erythroid maturation, where suppression
of HO expression plays a key role in cell differentiation.
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